Exploratory group (BeAM ≥0 mg/dL at week 24) | Main group (BeAM ≥0 mg/dL at week 24) | Proof-of-concept group* (BeAM ≥0 mg/dL at baseline) | |
---|---|---|---|
N=1188 | N=492 | N=299 | |
Age, mean (SD), years | 59.3 (9.5) | 59.4 (9.7) | 60.1 (9.3) |
Male, n (%) | 676 (56.9) | 255 (51.8) | 157 (52.5) |
White, n (%) | 1046 (93.6)† | 421 (92.7)‡ | 278 (93.0) |
Diabetes duration, mean (SD), years | 9.1 (6.0) | 9.5 (6.1) | 11.8 (7.00) |
Weight, mean (SD), kg | 87.7 (16.1) | 86.3 (15.7) | 86.4 (19.6) |
BMI, mean (SD), kg/m2 | 30.3 (4.5) | 30.0 (4.3) | 32.1 (18.4) |
FPG, mg/dL | 195.1 (46.9) | 199.6 (47.0) | 131.1 (42.5) |
A1C, % | |||
Baseline, mean (SD) | 8.72 (0.94) | 9.05 (0.94) | 8.38 (1.01) |
Week 24, mean (SD) | 7.06 (0.90) | 7.81 (0.74) | 7.15 (0.83) |
*Baseline values obtained after basal insulin optimization.
†N=1117.
‡N=454.
BMI, body mass index; FPG, fasting plasma glucose.